Please use this identifier to cite or link to this item:
https://hdl.handle.net/10216/149762| Author(s): | Mota, D Rama, TA Severo, M Moreira, A |
| Title: | Potential cancer risk with omalizumab? A disproportionality analysis of the WHO's VigiBase pharmacovigilance database |
| Publisher: | Wiley |
| Issue Date: | 2021 |
| Abstract: | Letter to the editor |
| DOI: | 10.1111/all.15008 |
| URI: | https://hdl.handle.net/10216/149762 |
| Source: | Allergy. 2021 Oct;76(10):3209-3211 |
| Document Type: | Outra Publicação em Revista Científica Internacional |
| Rights: | restrictedAccess |
| Appears in Collections: | ISPUP - Outra Publicação em Revista Científica Internacional |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| mota-a-2021.pdf Restricted Access | 230.3 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.